$35.66
0.842.43%
At close: -
$35.66
0.000.00%
After Hours: Apr 11, 4:00 PM EDT
Comments
Loading...
Akero Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:AKRO | Benzinga
Akero Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
May 9
EPS Estimate
$-0.990
Quarterly Revenue Estimate
–
Annual Revenue
(as of Dec 31)
(as of Dec 31)
–
Analyze the earnings history of Akero Therapeutics using advanced sorting and filters.
| Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AKRO | Akero Therapeutics | -$0.90 | -$0.99 | — | — | $0.00 | — | — | — | 05/09/2025 | Get Alert |
| AKRO | Akero Therapeutics | -$0.99 | -$1.13 | -$0.99 | 12.39% | $0.00 | — | $0.00 | — | 02/28/2025 | Get Alert |
| AKRO | Akero Therapeutics | -$0.71 | -$0.90 | -$1.05 | -16.67% | $0.00 | — | $0.00 | — | 11/08/2024 | Get Alert |
| AKRO | Akero Therapeutics | -$0.60 | -$0.90 | -$0.81 | 10.00% | $0.00 | — | $0.00 | — | 08/09/2024 | Get Alert |
| AKRO | Akero Therapeutics | -$0.55 | -$0.95 | -$0.90 | 5.26% | $0.00 | — | $0.00 | — | 05/10/2024 | Get Alert |
| AKRO | Akero Therapeutics | -$0.49 | -$0.86 | -$0.99 | -15.12% | $0.00 | — | $0.00 | — | 02/29/2024 | Get Alert |
| AKRO | Akero Therapeutics | -$0.92 | -$0.68 | -$0.71 | -4.41% | $0.00 | — | $0.00 | — | 11/13/2023 | Get Alert |
| AKRO | Akero Therapeutics | -$0.77 | -$0.63 | -$0.60 | 4.76% | $0.00 | — | $0.00 | — | 08/11/2023 | Get Alert |
| AKRO | Akero Therapeutics | -$0.74 | -$0.67 | -$0.55 | 17.91% | $0.00 | — | $0.00 | — | 05/15/2023 | Get Alert |
| AKRO | Akero Therapeutics | -$0.93 | -$0.80 | -$0.49 | 38.75% | $0.00 | — | $0.00 | — | 03/17/2023 | Get Alert |
| AKRO | Akero Therapeutics | -$0.70 | -$0.74 | -$0.92 | -24.32% | $0.00 | — | $0.00 | — | 11/04/2022 | Get Alert |
| AKRO | Akero Therapeutics | -$0.83 | -$0.86 | -$0.77 | 10.47% | $0.00 | — | $0.00 | — | 08/04/2022 | Get Alert |
| AKRO | Akero Therapeutics | -$0.43 | -$0.80 | -$0.74 | 7.50% | $0.00 | — | $0.00 | — | 05/06/2022 | Get Alert |
| AKRO | Akero Therapeutics | -$0.86 | -$0.82 | -$0.93 | -13.41% | $0.00 | — | $0.00 | — | 02/25/2022 | Get Alert |
| AKRO | Akero Therapeutics | -$0.63 | -$0.91 | -$0.70 | 23.08% | $0.00 | — | $0.00 | — | 11/12/2021 | Get Alert |
| AKRO | Akero Therapeutics | -$0.57 | -$0.75 | -$0.83 | -10.67% | $0.00 | — | $0.00 | — | 08/13/2021 | Get Alert |
| AKRO | Akero Therapeutics | -$0.42 | -$0.92 | -$0.43 | 53.26% | $0.00 | — | $0.00 | — | 05/13/2021 | Get Alert |
| AKRO | Akero Therapeutics | -$0.55 | — | -$0.86 | — | $0.00 | — | $0.00 | — | 03/16/2021 | Get Alert |
| AKRO | Akero Therapeutics | -$0.56 | — | -$0.63 | — | $0.00 | — | $0.00 | — | 11/12/2020 | Get Alert |
| AKRO | Akero Therapeutics | -$2.21 | — | -$0.57 | — | $0.00 | — | $0.00 | — | 08/12/2020 | Get Alert |
| AKRO | Akero Therapeutics | — | — | -$0.42 | — | — | — | $0.00 | — | 05/13/2020 | Get Alert |
Akero Therapeutics (AKRO) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q4 | 2025-02-28 | $-0.99 | $-1.13 | 12.4 % |
| Q3 | 2024-11-08 | $-1.05 | $-0.90 | -16.7 % |
| Q2 | 2024-08-09 | $-0.81 | $-0.90 | 10.0 % |
| Q1 | 2024-05-10 | $-0.90 | $-0.95 | 5.26 % |
Akero Therapeutics (AKRO) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
FAQ
When is Akero Therapeutics (NASDAQ:AKRO) reporting earnings?
Akero Therapeutics (AKRO) is scheduled to report earnings on May 9, 2025. The last reported earnings were for reported on February 28, 2025 for Q4.
What were the latest earnings per share (EPS) for Akero Therapeutics (NASDAQ:AKRO)?
The Actual EPS was $-0.99, which beat the estimate of $-1.13.
What were Akero Therapeutics’s (NASDAQ:AKRO) revenues?
The Actual Revenue was $0K, which hit the estimate of $0K.
Browse earnings estimates, EPS, and revenue on all stocks.